默沙东-话题@MedSci

#默沙东#

121篇内容 | 4305人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259978, encodeId=07b412599e87b, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=HIV口服“疫苗”时代到来！默沙东口服长效新药开展III期临床, objectType=article, longId=203221, objectId=df78203221cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df78203221cf, replyNumber=0, likeNumber=82, createdTime=2020-11-11, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df78203221cf, moduleTitle=HIV口服“疫苗”时代到来！默沙东口服长效新药开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df78203221cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259976, encodeId=7fbb12599e633, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=在全球针对30多种癌症开展1300多项临床实验默沙东全力 “探索肿瘤治疗未来”, objectType=article, longId=203169, objectId=71e820316945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71e820316945, replyNumber=0, likeNumber=68, createdTime=2020-11-10, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71e820316945, moduleTitle=在全球针对30多种癌症开展1300多项临床实验默沙东全力 “探索肿瘤治疗未来”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71e820316945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259975, encodeId=ea6612599e5be, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市, objectType=article, longId=202883, objectId=f95120288352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f95120288352, replyNumber=0, likeNumber=57, createdTime=2020-11-05, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f95120288352, moduleTitle=默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f95120288352)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259974, encodeId=37bb12599e4c0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=吉利德和默沙东双双出手，ADC领域四年后有望诞生超10亿美金新药, objectType=article, longId=200725, objectId=d906200e2522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d906200e2522, replyNumber=0, likeNumber=68, createdTime=2020-09-17, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d906200e2522, moduleTitle=吉利德和默沙东双双出手，ADC领域四年后有望诞生超10亿美金新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d906200e2522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259973, encodeId=2b8112599e391, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=年底有望双双上市？默沙东和辉瑞打响下一代肺炎球菌疫苗之战, objectType=article, longId=200556, objectId=2008200556fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2008200556fd, replyNumber=0, likeNumber=65, createdTime=2020-09-12, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2008200556fd, moduleTitle=年底有望双双上市？默沙东和辉瑞打响下一代肺炎球菌疫苗之战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2008200556fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259972, encodeId=e3d012599e292, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东向FDA申请扩展HPV疫苗Gardasil，用于预防口咽癌, objectType=article, longId=195929, objectId=b989195929a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b989195929a3, replyNumber=0, likeNumber=60, createdTime=2020-06-17, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b989195929a3, moduleTitle=默沙东向FDA申请扩展HPV疫苗Gardasil，用于预防口咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b989195929a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259971, encodeId=2f2712599e1b8, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=FDA批准默沙东的抗生素组合Recarbrio，治疗细菌性肺炎, objectType=article, longId=195446, objectId=495f195446c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=495f195446c7, replyNumber=0, likeNumber=71, createdTime=2020-06-09, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=495f195446c7, moduleTitle=FDA批准默沙东的抗生素组合Recarbrio，治疗细菌性肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=495f195446c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259970, encodeId=48ea12599e0f9, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=2020 Q1各大药企收入排名，强生，罗氏，诺华，默沙东，辉瑞，礼来，阿斯利康......, objectType=article, longId=193435, objectId=cdbc1934355a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdbc1934355a, replyNumber=0, likeNumber=69, createdTime=2020-05-05, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdbc1934355a, moduleTitle=2020 Q1各大药企收入排名，强生，罗氏，诺华，默沙东，辉瑞，礼来，阿斯利康......, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdbc1934355a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259969, encodeId=2cc4125996919, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, objectType=article, longId=188050, objectId=0cde18805010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cde18805010, replyNumber=0, likeNumber=62, createdTime=2020-02-16, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cde18805010, moduleTitle=默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cde18805010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259968, encodeId=548b125996807, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=重磅！默沙东将分拆为两家公司，专注研发创新生物制药, objectType=article, longId=187562, objectId=75ea18e562d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75ea18e562d0, replyNumber=0, likeNumber=85, createdTime=2020-02-07, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75ea18e562d0, moduleTitle=重磅！默沙东将分拆为两家公司，专注研发创新生物制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75ea18e562d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259967, encodeId=2850125996ef2, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东的PARP抑制剂Lynparza治疗卵巢癌获美国优先审查, objectType=article, longId=186379, objectId=d24f1863e995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d24f1863e995, replyNumber=0, likeNumber=64, createdTime=2020-01-18, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d24f1863e995, moduleTitle=默沙东的PARP抑制剂Lynparza治疗卵巢癌获美国优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d24f1863e995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259966, encodeId=73ba125996629, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, objectType=article, longId=185921, objectId=fcce18592178, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcce18592178, replyNumber=0, likeNumber=64, createdTime=2020-01-10, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcce18592178, moduleTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcce18592178)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259965, encodeId=22fd125996526, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=乙肝疫苗技术转让中国30周年，默沙东参与者追忆历史细节, objectType=article, longId=182830, objectId=169518283046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=169518283046, replyNumber=0, likeNumber=117, createdTime=2019-11-12, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=169518283046, moduleTitle=乙肝疫苗技术转让中国30周年，默沙东参与者追忆历史细节, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=169518283046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259964, encodeId=fe3a125996481, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=前高管携大量研发机密跳槽辉瑞，后知后觉的默沙东能否跑赢这场疫苗大战？, objectType=article, longId=181181, objectId=131018118166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=131018118166, replyNumber=0, likeNumber=60, createdTime=2019-10-16, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=131018118166, moduleTitle=前高管携大量研发机密跳槽辉瑞，后知后觉的默沙东能否跑赢这场疫苗大战？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=131018118166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259963, encodeId=73f51259963b7, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东“免疫+靶向”组合获欧盟批准一线治疗晚期肾癌, objectType=article, longId=178994, objectId=25591e89942d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25591e89942d, replyNumber=0, likeNumber=53, createdTime=2019-09-07, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25591e89942d, moduleTitle=默沙东“免疫+靶向”组合获欧盟批准一线治疗晚期肾癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25591e89942d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259962, encodeId=c9c81259962e9, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=香港议员要求默沙东公布供应正货疫苗诊所名单，避免水货牟利, objectType=article, longId=167803, objectId=2aa816e8039f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2aa816e8039f, replyNumber=0, likeNumber=52, createdTime=2019-06-08, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2aa816e8039f, moduleTitle=香港议员要求默沙东公布供应正货疫苗诊所名单，避免水货牟利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2aa816e8039f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259961, encodeId=979e125996165, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=“医二代”变多，日本网红眼药水被召回，默沙东K药单药疗法三期失败, objectType=article, longId=166910, objectId=06a21669103b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06a21669103b, replyNumber=0, likeNumber=61, createdTime=2019-05-28, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06a21669103b, moduleTitle=“医二代”变多，日本网红眼药水被召回，默沙东K药单药疗法三期失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06a21669103b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259960, encodeId=aea6125996071, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东否认向香港环亚供应HPV疫苗，港媒报医生联合订针由来已久, objectType=article, longId=165896, objectId=74261658968d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74261658968d, replyNumber=0, likeNumber=92, createdTime=2019-05-13, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74261658968d, moduleTitle=默沙东否认向香港环亚供应HPV疫苗，港媒报医生联合订针由来已久, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74261658968d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259959, encodeId=b2041259959b6, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=HPV疫苗市场默沙东一家独大，急追的国内厂商能否分一杯羹？, objectType=article, longId=165606, objectId=9ab316560665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ab316560665, replyNumber=0, likeNumber=89, createdTime=2019-05-09, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ab316560665, moduleTitle=HPV疫苗市场默沙东一家独大，急追的国内厂商能否分一杯羹？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ab316560665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259958, encodeId=3f6c12599586e, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东的PD-1单抗Keytruda获FDA批准治疗新的非小细胞肺癌亚型, objectType=article, longId=164162, objectId=4d0c164162a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d0c164162a0, replyNumber=0, likeNumber=59, createdTime=2019-04-14, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d0c164162a0, moduleTitle=默沙东的PD-1单抗Keytruda获FDA批准治疗新的非小细胞肺癌亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d0c164162a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

默沙东

2020-05-29

yese (审核中...)

前往app查看评论内容

#默沙东#

HIV口服“疫苗”时代到来！默沙东口服长效新药开展III期临床

2020-11-11

yese (审核中...)

前往app查看评论内容

#默沙东#

在全球针对30多种癌症开展1300多项临床实验默沙东全力 “探索肿瘤治疗未来”

2020-11-10

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市

2020-11-05

yese (审核中...)

前往app查看评论内容

#默沙东#

吉利德和默沙东双双出手，ADC领域四年后有望诞生超10亿美金新药

2020-09-17

yese (审核中...)

前往app查看评论内容

#默沙东#

年底有望双双上市？默沙东和辉瑞打响下一代肺炎球菌疫苗之战

2020-09-12

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东向FDA申请扩展HPV疫苗Gardasil，用于预防口咽癌

2020-06-17

yese (审核中...)

前往app查看评论内容

#默沙东#

FDA批准默沙东的抗生素组合Recarbrio，治疗细菌性肺炎

2020-06-09

yese (审核中...)

前往app查看评论内容

#默沙东#

2020 Q1各大药企收入排名，强生，罗氏，诺华，默沙东，辉瑞，礼来，阿斯利康......

2020-05-05

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功

2020-02-16

yese (审核中...)

前往app查看评论内容

#默沙东#

重磅！默沙东将分拆为两家公司，专注研发创新生物制药

2020-02-07

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东的PARP抑制剂Lynparza治疗卵巢癌获美国优先审查

2020-01-18

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率

2020-01-10

yese (审核中...)

前往app查看评论内容

#默沙东#

乙肝疫苗技术转让中国30周年，默沙东参与者追忆历史细节

2019-11-12

yese (审核中...)

前往app查看评论内容

#默沙东#

前高管携大量研发机密跳槽辉瑞，后知后觉的默沙东能否跑赢这场疫苗大战？

2019-10-16

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东“免疫+靶向”组合获欧盟批准一线治疗晚期肾癌

2019-09-07

yese (审核中...)

前往app查看评论内容

#默沙东#

香港议员要求默沙东公布供应正货疫苗诊所名单，避免水货牟利

2019-06-08

yese (审核中...)

前往app查看评论内容

#默沙东#

“医二代”变多，日本网红眼药水被召回，默沙东K药单药疗法三期失败

2019-05-28

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东否认向香港环亚供应HPV疫苗，港媒报医生联合订针由来已久

2019-05-13

yese (审核中...)

前往app查看评论内容

#默沙东#

HPV疫苗市场默沙东一家独大，急追的国内厂商能否分一杯羹？

2019-05-09

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东的PD-1单抗Keytruda获FDA批准治疗新的非小细胞肺癌亚型

2019-04-14

科室
- - 订阅+
  - 更多科室
工具
服务